120 related articles for article (PubMed ID: 38629813)
1. Using haematological indices to predict impaired liver function in DTC patients.
Zhou Y; Chai H
Hell J Nucl Med; 2024; 27(1):2-7. PubMed ID: 38629813
[TBL] [Abstract][Full Text] [Related]
2. Biochemical Effects of Levothyroxine Withdrawal in Patients with Differentiated Thyroid Cancer.
Papadakis G; Kalaitzidou S; Triantafillou E; Drosou A; Kakava K; Dogkas N; Pappa T; Kaltzidou V; Tertipi A; Villiotou V; Pappas A
Anticancer Res; 2015 Dec; 35(12):6933-40. PubMed ID: 26637919
[TBL] [Abstract][Full Text] [Related]
3. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
4. Levothyroxine-induced serum free thyroxine response following radioactive iodine administration in patients thyroidectomized for differentiated thyroid cancer: A randomized controlled trial.
Marina M; Maglietta G; De Filpo G; Aloe R; Gnocchi C; Iezzi E; Caminiti C; Ceresini G
Endocrine; 2022 Aug; 77(2):340-348. PubMed ID: 35751777
[TBL] [Abstract][Full Text] [Related]
5. Retrospective study of the influence of hypothyroidism on liver function before radioiodine therapy in China: a comparison analysis based on patients with differentiated thyroid cancer.
Ji Y; Zheng W; Meng Z; Wu C; Tan J; Wang R
BMJ Open; 2022 Jan; 12(1):e045562. PubMed ID: 35042702
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning.
Chow SM; Au KH; Choy TS; Lee SH; Yeung NY; Leung A; Leung A; Leung HL; Shek CC; Law SC
Laryngoscope; 2006 Nov; 116(11):2060-6. PubMed ID: 17075410
[TBL] [Abstract][Full Text] [Related]
7. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma.
Horie I; Ando T; Imaizumi M; Usa T; Kawakami A
Endocr Pract; 2015 May; 21(5):488-94. PubMed ID: 25667379
[TBL] [Abstract][Full Text] [Related]
8. Effects of thyroxine withdrawal in biochemical parameters and cardiac function and structure in patients with differentiated thyroid cancer.
Chrisoulidou A; Pazaitou-Panayiotou K; Kaprara A; Platoyiannis D; Lafaras C; Boudina M; Georgiou E; Drimonitis A; Bischiniotis T; Vainas I
Minerva Endocrinol; 2006 Jun; 31(2):173-8. PubMed ID: 16682940
[TBL] [Abstract][Full Text] [Related]
9. Hashimoto's thyroiditis pathology and risk for thyroid cancer.
Paparodis R; Imam S; Todorova-Koteva K; Staii A; Jaume JC
Thyroid; 2014 Jul; 24(7):1107-14. PubMed ID: 24708347
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
11. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
12. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
[TBL] [Abstract][Full Text] [Related]
13. Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation.
Matrone A; Gambale C; Piaggi P; Viola D; Giani C; Agate L; Bottici V; Bianchi F; Materazzi G; Vitti P; Molinaro E; Elisei R
J Clin Endocrinol Metab; 2017 Mar; 102(3):893-902. PubMed ID: 27929713
[TBL] [Abstract][Full Text] [Related]
14. Abnormal Brain Glucose Metabolism in Papillary Thyroid Cancer Patients 4 Weeks After Withdrawal of Levothyroxine: A Cross-Sectional Study Using
Wu SQ; Feng F; Zou RJ; Fu HL; Sun JW; Jia XZ; Yin YF; Wang H
Front Endocrinol (Lausanne); 2021; 12():595933. PubMed ID: 33776909
[TBL] [Abstract][Full Text] [Related]
15. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
16. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
Mousa U; Yikilmaz AS; Nar A
Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
[TBL] [Abstract][Full Text] [Related]
17. Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer.
Hu T; Meng Z; Zhang G; Jia Q; Tan J; Zheng W; Wang R; Li X; Liu N; Zhou P; Upadhyaya A
Medicine (Baltimore); 2016 Aug; 95(35):e4451. PubMed ID: 27583853
[TBL] [Abstract][Full Text] [Related]
18. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
Altuntaş SÇ; Hocaoğlu Ç
Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation.
Iakovou I; Goulis DG; Tsinaslanidou Z; Giannoula E; Katsikaki G; Konstantinidis I
Head Neck; 2016 Apr; 38 Suppl 1():E227-30. PubMed ID: 25537365
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
